$2.35T
Total marketcap
$85.46B
Total volume
BTC 50.06%     ETH 15.38%
Dominance

BioSyent BIOYF Stock

6.27 USD {{ price }} -0.397458% {{change_pct}}%
Exchange
Other OTC
Market Cap
73.42M USD
LOW - HIGH [24H]
6.27 - 6.29 USD
VOLUME [24H]
2.13K USD
{{ volume }}
P/E Ratio
16.06
Earnings per share
0.39 USD

BioSyent Price Chart

BioSyent BIOYF Financial and Trading Overview

BioSyent stock price 6.27 USD
Previous Close 5.39 USD
Open 5.39 USD
Bid 0 USD x 0
Ask 0 USD x 0
Day's Range 5.39 - 5.39 USD
52 Week Range 4.69 - 6.34 USD
Volume 2K USD
Avg. Volume 3.1K USD
Market Cap 65.36M USD
Beta (5Y Monthly) 0.791245
PE Ratio (TTM) 17.966665
EPS (TTM) 0.39 USD
Forward Dividend & Yield 0.12 (2.20%)
Ex-Dividend Date June 1, 2023
1y Target Est N/A

BIOYF Valuation Measures

Enterprise Value 40.28M USD
Trailing P/E 17.966665
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 2.3878648
Price/Book (mrq) 1.9507781
Enterprise Value/Revenue 1.472
Enterprise Value/EBITDA 6.185

Trading Information

BioSyent Stock Price History

Beta (5Y Monthly) 0.791245
52-Week Change -8.48%
S&P500 52-Week Change 20.43%
52 Week High 6.34 USD
52 Week Low 4.69 USD
50-Day Moving Average 5.62 USD
200-Day Moving Average 5.49 USD

BIOYF Share Statistics

Avg. Volume (3 month) 3.1K USD
Avg. Daily Volume (10-Days) 1.8K USD
Shares Outstanding 12.09M
Float 9.43M
Short Ratio N/A
% Held by Insiders 40.77%
% Held by Institutions 1.31%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0.08
Trailing Annual Dividend Yield 1.48%
5 Year Average Dividend Yield N/A
Payout Ratio 0.1975
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 18.43%
Operating Margin (ttm) 22.87%
Gross Margin 82.57%
EBITDA Margin 23.79%

Management Effectiveness

Return on Assets (ttm) 10.21%
Return on Equity (ttm) 15.41%

Income Statement

Revenue (ttm) 27.37M USD
Revenue Per Share (ttm) 2.24 USD
Quarterly Revenue Growth (yoy) -7.90%
Gross Profit (ttm) 22.86M USD
EBITDA 6.51M USD
Net Income Avi to Common (ttm) 5.05M USD
Diluted EPS (ttm) 0.3
Quarterly Earnings Growth (yoy) -26.00000000000000000000000000000000%

Balance Sheet

Total Cash (mrq) 26.25M USD
Total Cash Per Share (mrq) 2.17 USD
Total Debt (mrq) 1.35M USD
Total Debt/Equity (mrq) 4.05 USD
Current Ratio (mrq) 9.017
Book Value Per Share (mrq) 2.763

Cash Flow Statement

Operating Cash Flow (ttm) 3.96M USD
Levered Free Cash Flow (ttm) 2.59M USD

Profile of BioSyent

Country United States
State ON
City Mississauga
Address 2476 Argentia Road
ZIP L5N 6M1
Phone 905-206-0013
Website https://www.biosyent.com
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees N/A

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water or mixing oral iron supplement; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency, as well as Feramax Pd Maintenance 45, a chewable, orange-flavored iron supplement. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Q&A For BioSyent Stock

What is a current BIOYF stock price?

BioSyent BIOYF stock price today per share is 6.27 USD.

How to purchase BioSyent stock?

You can buy BIOYF shares on the Other OTC exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for BioSyent?

The stock symbol or ticker of BioSyent is BIOYF.

Which industry does the BioSyent company belong to?

The BioSyent industry is Drug Manufacturers-Specialty & Generic.

How many shares does BioSyent have in circulation?

The max supply of BioSyent shares is 11.72M.

What is BioSyent Price to Earnings Ratio (PE Ratio)?

BioSyent PE Ratio is 16.06410200 now.

What was BioSyent earnings per share over the trailing 12 months (TTM)?

BioSyent EPS is 0.39 USD over the trailing 12 months.

Which sector does the BioSyent company belong to?

The BioSyent sector is Healthcare.